Point-of-Care Testing (POCT) for Inflammatory Market Trends and Forecast
The future of the global point-of-care testing (POCT) for inflammatory market looks promising with opportunities in the c-reactive protein (CRP) test, procalcitonin (PCT) test, interleukin 6 (IL-6) test, and serum amyloid a (SAA) test markets. The global point-of-care testing (POCT) for inflammatory market is expected to grow with a CAGR of 8.2% from 2025 to 2031. The major drivers for this market are the prevalence of chronic inflammatory diseases and the rising healthcare access in remote areas.
• Lucintel forecasts that, within the type category, immunochromatography is expected to witness the highest growth over the forecast period.
• Within the application category, the c-reactive protein (CRP) test is expected to witness the highest growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.
Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.
Emerging Trends in the Point-of-care Testing (POCT) for Inflammatory Market
As the global demand for faster, more efficient testing solutions rises, several emerging trends are shaping the Point-of-Care Testing (POCT) market for inflammatory diseases. These trends focus on technological advancements, improving patient access, and enhancing diagnostic accuracy. Here are five key trends that are reshaping the market.
• Integration with Digital Health Platforms: Digital health integration is a key trend, where POCT devices are increasingly being connected to mobile apps and healthcare platforms. These integrations allow healthcare providers to remotely monitor patientsÄX%$%X inflammation levels, improving patient management and decision-making. Real-time data transmission helps in tracking disease progression and modifying treatments, offering convenience for both patients and clinicians. As telemedicine continues to grow, digital health integration is expected to become a standard feature of POCT solutions.
• Development of Multiplex Tests: Multiplex testing, which allows for the simultaneous detection of multiple inflammatory markers, is gaining traction in the POCT market. These tests are highly beneficial as they enable comprehensive monitoring of different inflammatory pathways in a single sample, saving time and improving diagnostic efficiency. By measuring various biomarkers in a single test, multiplex POCT can improve the accuracy of diagnoses and help in the better management of complex conditions like rheumatoid arthritis and autoimmune diseases. This trend is enhancing the effectiveness of point-of-care diagnostics.
• Wearable and Home-based POCT Devices: The development of wearable devices and home-based POCT systems is revolutionizing the market. These devices enable patients to monitor their inflammation levels from the comfort of their homes, reducing the need for frequent hospital visits. These systems not only increase convenience but also allow for continuous monitoring, which is crucial for chronic disease management. With the increasing shift toward personalized medicine, wearable POCT devices are expected to become a cornerstone in managing inflammatory diseases, particularly in the aging population.
• Increased Focus on Biomarkers for Early Detection: Early detection of inflammatory diseases is a growing focus, with a rising emphasis on the identification of novel biomarkers that can be detected using POCT. Biomarkers like CRP, IL-6, and TNF-alpha are already widely used in inflammation testing, but advancements in molecular testing are enabling the identification of additional biomarkers that may offer more precise insights into inflammation. This focus on early detection is particularly important in the management of chronic inflammatory conditions and offers the potential for better long-term patient outcomes.
• Regulatory Support for At-Home Testing: Regulatory agencies are increasingly supporting at-home testing solutions, allowing patients to monitor their inflammatory conditions independently. This regulatory shift is paving the way for the widespread use of over-the-counter POCT devices, especially for managing chronic conditions like rheumatoid arthritis. By facilitating easier access to testing, regulatory support encourages patient empowerment, reduces healthcare costs, and promotes proactive disease management. Governments are also backing this shift by providing frameworks to ensure the safety and reliability of at-home tests.
These emerging trends—digital health integration, multiplex testing, wearable devices, early detection biomarkers, and regulatory support for at-home testing—are significantly reshaping the Point-of-Care Testing market for inflammatory diseases. These trends are improving diagnostic capabilities, enhancing patient access, and enabling better management of chronic conditions. As these trends continue to evolve, they will likely drive further growth and innovation in the POCT market.
Recent Development in the Point-of-care Testing (POCT) for Inflammatory Market
Recent developments in the Point-of-Care Testing (POCT) market for inflammatory diseases have been fueled by technological advancements and increasing healthcare demands. Key developments in the market include the creation of faster, more accurate testing systems, integration with digital tools, and greater accessibility to POCT in various healthcare settings. Here are five major developments that are driving growth in the market.
• Advancements in Portable Testing Devices: Portable POCT devices for inflammatory diseases are becoming more common, allowing healthcare providers to conduct tests quickly and efficiently in various settings, such as clinics, emergency rooms, and at home. These devices are compact, user-friendly, and provide accurate results in real time. The portability and ease of use make them ideal for on-site testing, improving patient care by offering immediate information that aids in treatment decisions. This development is enhancing the speed and convenience of diagnosing inflammatory diseases.
• Improved Accuracy with Biomarker Detection: Recent innovations in POCT for inflammation have led to enhanced accuracy through the use of more sensitive biomarker detection technologies. New tests can detect low levels of inflammatory markers like CRP and PCT with greater precision, allowing for earlier detection and better disease monitoring. This improvement in accuracy is crucial for making timely interventions and adjusting treatment regimens, leading to better patient outcomes. Additionally, these more accurate tests are reducing the number of false positives and negatives that can affect patient management.
• Collaboration with Telemedicine Platforms: There has been an increase in collaborations between POCT device manufacturers and telemedicine platforms to integrate real-time data from inflammatory tests into digital health records. These collaborations facilitate remote monitoring of patients, enabling healthcare providers to track inflammation levels without requiring in-person visits. This integration improves access to care, especially in remote or underserved regions, and allows clinicians to provide continuous care to patients with chronic inflammatory diseases. The use of digital platforms enhances the management of long-term conditions.
• Development of Rapid, Multiplex Testing Kits: Multiplex testing kits, which can simultaneously test for multiple inflammatory markers, are a significant advancement in the POCT market. These kits allow healthcare providers to obtain a more comprehensive view of a patient’s inflammatory condition, improving diagnostic accuracy and treatment planning. By reducing the time and cost associated with running separate tests, multiplex kits also make it easier for healthcare providers to monitor complex diseases like autoimmune disorders, leading to better patient management.
• Regulatory Approvals for At-Home Testing Devices: The approval of at-home testing devices for inflammation by regulatory bodies like the FDA has opened up new opportunities in the POCT market. These devices, which allow patients to test their inflammation levels at home, are expected to become a key tool for managing chronic inflammatory diseases. By offering patients more autonomy and reducing the need for frequent doctor visits, at-home testing devices can help manage diseases like rheumatoid arthritis more effectively. These devices are expected to play an essential role in the future of personalized healthcare.
Recent developments in POCT for inflammatory diseases, including advancements in portable testing devices, improved accuracy, telemedicine collaborations, multiplex testing, and at-home testing approvals, are transforming the market. These innovations are making diagnostic testing faster, more accurate, and more accessible, leading to improved disease management and better patient outcomes.
Strategic Growth Opportunities in the Point-of-care Testing (POCT) for Inflammatory Market
As the global healthcare landscape evolves, the Point-of-Care Testing (POCT) market for inflammatory diseases presents several strategic growth opportunities. These opportunities are primarily driven by advancements in technology, patient demand for quicker diagnostic solutions, and the ongoing need for chronic disease management. By focusing on key applications such as clinical diagnostics, home care, and multiplex testing, the POCT market for inflammatory diseases can expand significantly. Below are five key growth opportunities in this market.
• Clinical Diagnostics for Chronic Inflammatory Diseases: POCT has significant growth potential in clinical diagnostics for chronic inflammatory diseases like rheumatoid arthritis and inflammatory bowel disease. These tests enable early detection and continuous monitoring, which are essential for managing long-term conditions. By providing rapid results at the point of care, POCT can reduce the time it takes to initiate treatment, improving patient outcomes. The shift toward personalized medicine, where treatments are tailored based on individual inflammatory markers, also presents an opportunity for growth in this application.
• Home-based Testing Solutions: Home-based POCT devices for inflammatory diseases present a promising growth opportunity, particularly as the demand for patient autonomy increases. Patients can track their inflammation levels from the comfort of their homes, improving disease management and reducing the need for hospital visits. These tests are especially beneficial for chronic disease patients who require regular monitoring. By providing affordable, easy-to-use devices, manufacturers can tap into the growing home healthcare market, offering patients more convenient ways to manage their condition.
• Emergency and Acute Care Testing: The growing need for quick diagnosis in emergency and acute care settings creates an opportunity for POCT devices that can rapidly detect inflammatory markers like CRP and PCT. Early detection of inflammation can significantly impact the treatment of conditions like sepsis, autoimmune diseases, and infections. As emergency care facilities seek faster, more reliable diagnostic tools, POCT devices designed for rapid testing are becoming increasingly important. Manufacturers who can develop accurate and portable testing devices for acute settings are well-positioned to meet this growing demand.
• Multiplex Testing for Complex Inflammatory Diseases: Multiplex testing solutions that allow simultaneous detection of various inflammatory markers are gaining traction in the market. These solutions offer a more comprehensive approach to diagnosing complex diseases like autoimmune disorders, where multiple inflammatory pathways are involved. By streamlining the testing process, multiplex kits reduce diagnostic delays and improve treatment accuracy. This trend is expected to drive growth in both clinical and research settings as healthcare providers seek more efficient ways to manage patients with multifaceted inflammatory conditions.
• Integration with Digital Health and Telemedicine: The integration of POCT devices with digital health platforms and telemedicine solutions offers a significant growth opportunity. By enabling remote monitoring and data sharing, these integrated systems make it easier for healthcare providers to track inflammation levels in real time. This integration is particularly beneficial for patients in rural or underserved areas, where access to healthcare is limited. As telemedicine becomes more widespread, the demand for integrated POCT solutions is expected to increase, enhancing patient care and overall healthcare efficiency.
Strategic growth opportunities in the POCT for inflammatory diseases market lie in clinical diagnostics, home-based testing, emergency care, multiplex testing, and digital health integration. These areas are shaping the future of inflammation management and creating significant potential for market expansion. Manufacturers focusing on these applications will be well-positioned to capitalize on the growing demand for rapid, accurate, and accessible testing solutions for inflammatory conditions.
Point-of-care Testing (POCT) for Inflammatory Market Driver and Challenges
The Point-of-Care Testing (POCT) market for inflammatory diseases is influenced by several drivers and challenges that shape its growth. Technological advancements, healthcare demand for quick diagnostics, and regulatory changes contribute to the market’s expansion. However, challenges such as regulatory hurdles, high costs, and market competition also impact the marketÄX%$%Xs trajectory. Understanding these drivers and challenges is essential for stakeholders aiming to succeed in the market.
The factors responsible for driving the point-of-care testing (POCT) for inflammatory market include:
1. Technological Advancements in Testing Devices: Technological innovations in POCT devices are one of the primary drivers of the market. With the advent of more sensitive and accurate biomarkers, POCT for inflammatory diseases can deliver faster and more reliable results. Furthermore, advancements in miniaturization and integration with digital platforms are making POCT devices more accessible and easier to use. These improvements are expanding the range of POCT applications and driving market growth.
2. Rising Prevalence of Chronic Inflammatory Diseases: The increasing prevalence of chronic inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and cardiovascular conditions, is driving the demand for POCT solutions. These conditions require continuous monitoring and early intervention, which makes point-of-care testing an ideal solution. The rising number of patients needing management for these conditions is propelling the demand for accessible and efficient testing.
3. Demand for Quick and Accurate Diagnostics: The demand for rapid, accurate diagnostics is a significant driver in the POCT market. Patients and healthcare providers require quick results, particularly in the management of acute conditions or flare-ups of chronic diseases. POCT devices that can deliver real-time results without the need for lab processing are highly valued in both emergency and routine care settings.
4. Patient-Centric Healthcare Model: The shift towards a more patient-centric healthcare model, where patients are empowered to monitor their health, is driving the growth of at-home POCT devices. Patients with chronic inflammatory conditions are seeking more autonomy in their healthcare management, and POCT solutions that offer this independence are in high demand. This model is also supported by the rise in telemedicine and remote care, making POCT an essential tool for long-term disease management.
5. Regulatory Support for Point-of-Care Devices: Governments and regulatory bodies are increasingly supportive of the development and approval of point-of-care diagnostic devices, streamlining the approval process and promoting innovation. This regulatory support is encouraging more manufacturers to enter the POCT market for inflammatory diseases, contributing to increased product availability and competition.
Challenges in the point-of-care testing (POCT) for inflammatory market are:
1. Regulatory Compliance and Approval Delays: One of the significant challenges in the POCT market is navigating the complex regulatory landscape. Different countries have varying regulations for point-of-care devices, which can lead to delays in product approval and market entry. Compliance with safety and performance standards is crucial, and manufacturers must ensure their devices meet stringent regulatory requirements.
2. High Costs of Development and Production: Developing and producing advanced POCT devices can be expensive, particularly for high-precision, biomarker-based tests. These high costs can limit the affordability of the devices, potentially restricting access to patients in low-income regions. Manufacturers need to find ways to reduce production costs while maintaining quality standards to remain competitive.
3. Market Fragmentation and Competition: The POCT market for inflammatory diseases is highly fragmented, with numerous players offering a variety of devices. This creates intense competition and makes it challenging for companies to differentiate their products. Additionally, smaller manufacturers may struggle to scale their operations or gain market share, creating barriers to entry and consolidation within the industry.
The major drivers in the POCT market for inflammatory diseases include technological advancements, rising prevalence of chronic conditions, demand for rapid diagnostics, a patient-centric healthcare model, and regulatory support. However, challenges such as regulatory compliance, high development costs, and market fragmentation need to be addressed. By overcoming these challenges, the POCT market for inflammatory diseases can continue to grow and improve patient outcomes.
List of Point-of-Care Testing (POCT) Companies for Inflammatory Market
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies point-of-care testing (POCT) companies for inflammatory market cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the point-of-care testing (POCT) companies for inflammatory market are profiled in this report include-
• Roche
• Abbott
• Siemens Healthineers
• Biomerieux
• Bio-Rad Laboratories
• Assure Tech
• Guangzhou Wondfo Biotech Co.
• Wuhan Easy Diagnosis
• Getein Biotech
• Hipro Biotechnology
Point-of-Care Testing (POCT) for Inflammatory Market by Segment
The study includes a forecast for the global point-of-care testing (POCT) for inflammatory market by type, application, and region.
Point-of-Care Testing (POCT) for Inflammatory Market by Type [Value from 2019 to 2031]:
• Based on Immunochromatography
• Based on Chemiluminescence
• Based on Microfluidic Chip
Point-of-Care Testing (POCT) for Inflammatory Market by Application [Value from 2019 to 2031]:
• C-Reactive Protein (CRP) Test
• Procalcitonin (PCT) Test
• Interleukin 6 (IL-6) Test
• Serum Amyloid A (SAA) Test
• Others
Point-of-Care Testing (POCT) for Inflammatory Market by Region [Value from 2019 to 2031]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
Country Wise Outlook for the Point-of-care Testing (POCT) for Inflammatory Market
The Point-of-Care Testing (POCT) market for inflammatory diseases is witnessing significant growth due to rising incidences of chronic inflammatory conditions and increasing demand for quick, on-site diagnostic solutions. Inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and psoriasis, require early detection and management, which drives the adoption of POCT solutions. These tests allow healthcare providers to monitor inflammation levels in patients more efficiently, reducing waiting times for results. As healthcare systems evolve, countries like the United States, China, Germany, India, and Japan are embracing innovations in POCT for inflammation management, which are transforming the healthcare landscape globally.
• United States: The U.S. market for POCT in inflammatory diseases has been bolstered by an increasing focus on early disease detection and home-based monitoring solutions. Advancements in rapid inflammatory markers such as C-reactive protein (CRP) and procalcitonin (PCT) tests are making it easier for healthcare providers to assess inflammation levels at the point of care. Furthermore, the COVID-19 pandemic accelerated the adoption of POCT, including tests for inflammatory biomarkers, as demand for quick diagnostics surged. A shift towards integrating POCT into routine clinical practice and home care settings is expected to continue as patients seek more accessible options for managing chronic conditions.
• China: In China, there has been a rapid expansion of POCT for inflammatory diseases due to the growing burden of inflammatory conditions such as rheumatoid arthritis and cardiovascular diseases. The Chinese government has been promoting the adoption of POCT to improve healthcare access, particularly in rural and underserved regions. Local manufacturers are also innovating to develop affordable and reliable inflammatory testing solutions tailored for the Chinese population. Additionally, collaborations between healthcare providers and technology companies are increasing, allowing for better integration of POCT into China’s healthcare infrastructure. The market is expected to expand further as awareness of these tests grows.
• Germany: The German market for POCT in inflammatory diseases is supported by the countryÄX%$%Xs robust healthcare system and advanced medical infrastructure. There is a growing emphasis on personalized healthcare, where inflammatory biomarkers such as CRP and ESR (erythrocyte sedimentation rate) are regularly tested to monitor the progression of diseases like rheumatoid arthritis and inflammatory bowel disease. Recent advancements include the development of portable, easy-to-use POCT devices that provide real-time results for patients and clinicians. Furthermore, GermanyÄX%$%Xs healthcare reforms aim to increase the accessibility and efficiency of diagnostic testing, making POCT a preferred choice for both hospitals and outpatient clinics.
• India: In India, the demand for POCT in inflammatory diseases is rising due to a significant increase in the incidence of conditions such as rheumatoid arthritis and diabetes, which can lead to inflammation. With a vast and diverse population, India faces challenges in providing widespread access to traditional lab-based testing, which has driven the adoption of POCT solutions. The Indian market is seeing innovations in affordable diagnostic tools for inflammatory diseases, particularly in rural areas. Additionally, India is focusing on improving healthcare infrastructure, which will continue to drive the expansion of POCT as part of a broader initiative to improve health outcomes for chronic disease management.
• Japan: The Japanese POCT market for inflammatory diseases has seen strong growth, driven by the countryÄX%$%Xs aging population and the rising prevalence of inflammatory conditions such as arthritis and cardiovascular diseases. Japan has introduced regulations that support the use of POCT devices in clinical and home care settings, making it easier for patients to monitor their condition independently. Japanese companies are at the forefront of developing highly accurate and portable POCT devices, which are gaining popularity among healthcare providers. With an increasing emphasis on elderly care, POCT for inflammatory diseases plays a crucial role in the management of age-related inflammatory conditions.
Features of the Global Point-of-Care Testing (POCT) for Inflammatory Market
Market Size Estimates: Point-of-care testing (POCT) for inflammatory market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Point-of-care testing (POCT) for inflammatory market size by type, application, and region in terms of value ($B).
Regional Analysis: Point-of-care testing (POCT) for inflammatory market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the point-of-care testing (POCT) for inflammatory market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the point-of-care testing (POCT) for inflammatory market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the growth forecast for point-of-care testing (POCT) for inflammatory market?
Answer: The global point-of-care testing (POCT) for inflammatory market is expected to grow with a CAGR of 8.2% from 2025 to 2031.
Q2. What are the major drivers influencing the growth of the point-of-care testing (POCT) for inflammatory market?
Answer: The major drivers for this market are the prevalence of chronic inflammatory diseases and the rising healthcare access in remote areas.
Q3. What are the major segments for point-of-care testing (POCT) for inflammatory market?
Answer: The future of the point-of-care testing (POCT) for inflammatory market looks promising with opportunities in the c-reactive protein (CRP) test, procalcitonin (PCT) test, interleukin 6 (IL-6) test, and serum amyloid a (SAA) test markets.
Q4. Who are the key point-of-care testing (POCT) companies for inflammatory market?
Answer: Some of the key point-of-care testing (POCT) companies for inflammatory market are as follows:
• Roche
• Abbott
• Siemens Healthineers
• Biomerieux
• Bio-Rad Laboratories
• Assure Tech
• Guangzhou Wondfo Biotech Co.
• Wuhan Easy Diagnosis
• Getein Biotech
• Hipro Biotechnology
Q5. Which point-of-care testing (POCT) for inflammatory market segment will be the largest in future?
Answer: Lucintel forecasts that, within the type category, immunochromatography is expected to witness the highest growth over the forecast period.
Q6. In point-of-care testing (POCT) for inflammatory market, which region is expected to be the largest in next 5 years?
Answer: In terms of region, APAC is expected to witness the highest growth over the forecast period.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the point-of-care testing (POCT) for inflammatory market by type (based on immunochromatography, based on chemiluminescence, and based on microfluidic chip), application (c-reactive protein (CRP) test, procalcitonin (PCT) test, interleukin 6 (IL-6) test, serum amyloid a (SAA) test, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Point-of-Care Testing (POCT) for Inflammatory Market, Point-of-Care Testing (POCT) for Inflammatory Market Size, Point-of-Care Testing (POCT) for Inflammatory Market Growth, Point-of-Care Testing (POCT) for Inflammatory Market Analysis, Point-of-Care Testing (POCT) for Inflammatory Market Report, Point-of-Care Testing (POCT) for Inflammatory Market Share, Point-of-Care Testing (POCT) for Inflammatory Market Trends, Point-of-Care Testing (POCT) for Inflammatory Market Forecast, Point-of-Care Testing (POCT) for Inflammatory Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.